Abcuro
Clinical-stage immunotherapies targeting pathogenic cytotoxic T cells in autoimmune disease.
$66MSeries D
Role not disclosedFC
Foresite Capital
Activity from announced rounds
Activity in this selectionBiotech
Foresite Capital is a healthcare investment firm identified by Abcuro and in its own Thyme Care portfolio record.
Recorded funding activity
Abcuro develops immunotherapies targeting pathogenic cytotoxic T cells. Thyme Care combines oncology care teams with technology, while Khartis develops oral medicines for immune and chronic diseases. The company histories distinguish care delivery from experimental drug development.
- Rounds participated in
- 5
- Confirmed lead rounds
- — 5 roles undisclosed
- New companies
- 5 First participation on record · 0 follow-on
- Funding in participating rounds
- $726M 5 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
5 in this selectionKhartis Therapeutics
Develops oral small molecule therapies for immunological and chronic diseases
$50MSeries B
Role not disclosedSlate Medicines
Advancing next-generation therapeutics for migraine and other headache disorders
$130MSeries A
Role not disclosedKorsana Biosciences
Develops therapies for neurodegenerative diseases.
$175MSeries A
Role not disclosedParabilis Medicines
Develops medicines targeting historically undruggable protein targets in cancer
$305MSeries F
Role not disclosed